Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revive Therapeutics Ltd (OP: RVVTF )

0.0375 -0.0003 (-0.79%)
Streaming Delayed Price Updated: 3:28 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 259,691
Open 0.0384
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0378
Today's Range 0.0375 - 0.0390
52wk Range 0.0296 - 0.3900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via Globe NewsWire
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via Globe NewsWire

Performance

YTD
-54.27%
-54.27%
1 Month
-62.54%
-62.54%
3 Month
-60.77%
-60.77%
6 Month
-87.34%
-87.34%
1 Year
-79.50%
-79.50%

More News

Read More
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Via Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Via Benzinga
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
From Revive Therapeutics Ltd.
Via Globe NewsWire
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Via Benzinga
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
From Revive Therapeutics Ltd.
Via Globe NewsWire
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via Globe NewsWire
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
Via Benzinga
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via Globe NewsWire
Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders
Via Benzinga
Revive Therapeutics Ltd. Closes $4.3 Million Offering
From Revive Therapeutics Ltd.
Via Globe NewsWire
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
From Revive Therapeutics Ltd.
Via Globe NewsWire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via Globe NewsWire
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
From Revive Therapeutics Ltd.
Via Globe NewsWire
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Via Benzinga
Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials
Via Benzinga
Revive Therapeutics Ltd. Expands Life Offering to Quebec
From Revive Therapeutics Ltd.
Via Globe NewsWire
Revive Therapeutics To Raise Up To $5M Via Private Placement
Via Benzinga
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
From Revive Therapeutics Ltd.
Via Globe NewsWire
Psychedelic Stock Gainers And Losers From November 30, 2022
Via Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From November 25, 2022
Via Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.